Evaluating the Balance Between Privacy and Access in Digital Information Sharing.

"Drs. Beesley and Rozenblum received support for article research from The Gordon and Betty Moore Foundation. Dr. Powell received funding from the University of Utah School of Medicine. Dr. Butler disclosed government work. Dr. Hopkins’ institution received funding from Intermountain Research and Medical Foundation. Drs. Rozenblum’s, Aboumatar’s, and Brown’s institutions received funding from The Gordon and Betty Moore Foundation. Dr. Rozenblum disclosed having equity in Hospitech Respiration Ltd. Dr. Sugarman is a member of Merck KGaA’s Bioethics Advisory Panel and Stem Cell Research Oversight Committee; a member of IQVIA’s Ethics Advisory Panel; a member of Aspen Neurosciences Scientific Advisory Board; a member of a Merck Data Monitoring Committee; a consultant to Biogen; and a consultant to Portola Pharmaceuticals Inc. None of these activities are related to the material discussed in this article. Dr. Sugarman received funding from Merck KGaA Bioethics Advisory Panel and Stem Cell Research Oversight Committee, IQVIA Ethics Advisory Panel, and Merck Data Monitoring Committee. The remaining authors have disclosed that they do not have any potential conflicts of interest."

"Drs. Beesley and Rozenblum received support for article research from The Gordon and Betty Moore Foundation. Dr. Powell received funding from the University of Utah School of Medicine. Dr. Butler disclosed government work. Dr. Hopkins’ institution received funding from Intermountain Research and Medical Foundation. Drs. Rozenblum’s, Aboumatar’s, and Brown’s institutions received funding from The Gordon and Betty Moore Foundation. Dr. Rozenblum disclosed having equity in Hospitech Respiration Ltd. Dr. Sugarman is a member of Merck KGaA’s Bioethics Advisory Panel and Stem Cell Research Oversight Committee; a member of IQVIA’s Ethics Advisory Panel; a member of Aspen Neurosciences Scientific Advisory Board; a member of a Merck Data Monitoring Committee; a consultant to Biogen; and a consultant to Portola Pharmaceuticals Inc. None of these activities are related to the material discussed in this article. Dr. Sugarman received funding from Merck KGaA Bioethics Advisory Panel and Stem Cell Research Oversight Committee, IQVIA Ethics Advisory Panel, and Merck Data Monitoring Committee. The remaining authors have disclosed that they do not have any potential conflicts of interest."